To ask the Secretary of State for Health and Social Care, what steps are being taken to ensure that the UK enters the top quartile of comparator countries for the speed of adoption and overall uptake of innovative treatments as recommended in the Life Sciences Industrial Strategy.
24 January 2018
Comparisons of uptake of medicines between different countries with different health systems are difficult and should be treated with caution. However, we are committed to working with industry on this issue and share the ambition to maximise the appropriate use of innovation in our system and tackle unwarranted variation in uptake. The Government and industry are currently working together through a series of workshops that will provide the foundation for the next medicines pricing scheme, and discussions around uptake, adoption and metrics have been a feature of those early meetings.
The recent Government and partner bodies response to the Accelerated Access Review sets out how we will work with industry and the health system to create a streamlined and sophisticated approvals system so that cost-effective breakthrough products – be they drugs, devices, digital or diagnostics – can get into the National Health Service as fast as possible.